This is a promotional website intended for UK healthcare professionals.

Colobreathe® (colistimethate sodium) Prescribing Information can be found here.
Adverse Event Reporting Information can be found at the end of this page.

About Essential Pharma
Menu
Packaging may vary

Effective Pseudomonas aeruginosa treatment for patients with cystic fibrosis (CF)1,2

Colobreathe® offers a convenient treatment regimen for managing Pseudomonas aeruginosa infections in people with CF1,2

Packaging may vary

Colobreathe® is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.

Consideration should be given to official guidance on the appropriate use of antibacterial active substances.2

Simplicity and convenience

Learn more about Colobreathe®’s simple regimen and explore convenience findings
Learn more

Non-inferiority to tobramycin

(demonstrated by Phase 3 study)

Explore findings from Phase 3 non-inferiority Freedom study1
Explore now

Colobreathe® resources

At Essential Pharma one of our goals is to ensure healthcare professionals have the tools needed to deliver optimal care and support their patients every step of their treatment journey
Discover available resources

CF, cystic fibrosis.

References:
1. Schuster A, Haliburn C, Döring G, et al. Thorax 2013;68:344–350.
2. Colobreathe® Summary of Product Characteristics. Available here.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for the MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Essential Pharma on +44 (0) 1423 850700 or at EssentialpharmaUK@EU.ProPharmaGroup.com.

Essential Pharma Ltd, 8A Crabtree Road, Egham, Surrey, TW20 8RN, United Kingdom
Colobreathe® is a registered trademark of Essential Pharma. Copyright © 2026 Essential Pharma
MAT-COL-GB-0002-1224 May 2025

crossmenuarrow-right